144 related articles for article (PubMed ID: 35007784)
1. Exosome-mediated delivery of transforming growth factor-β receptor 1 kinase inhibitors and toll-like receptor 7/8 agonists for combination therapy of tumors.
Lee JH; Song J; Kim IG; You G; Kim H; Ahn JH; Mok H
Acta Biomater; 2022 Mar; 141():354-363. PubMed ID: 35007784
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
[TBL] [Abstract][Full Text] [Related]
3. Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment.
Lin W; Li C; Xu N; Watanabe M; Xue R; Xu A; Araki M; Sun R; Liu C; Nasu Y; Huang P
Int J Nanomedicine; 2021; 16():2775-2787. PubMed ID: 33880023
[TBL] [Abstract][Full Text] [Related]
4. Nanoscale coordination polymer synergizes photodynamic therapy and toll-like receptor activation for enhanced antigen presentation and antitumor immunity.
Jiang X; Liu J; Lee MJ; Peng C; Luo T; Tillman L; Weichselbaum RR; Lin W
Biomaterials; 2023 Nov; 302():122334. PubMed ID: 37776767
[TBL] [Abstract][Full Text] [Related]
5. Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.
Moreno Ayala MA; Gottardo MF; Gori MS; Nicola Candia AJ; Caruso C; De Laurentiis A; Imsen M; Klein S; Bal de Kier Joffé E; Salamone G; Castro MG; Seilicovich A; Candolfi M
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1713-1732. PubMed ID: 28432455
[TBL] [Abstract][Full Text] [Related]
6. Sonodynamical reversion of immunosuppressive microenvironment in prostate cancer via engineered exosomes.
Wang D; Wan Z; Yang Q; Chen J; Liu Y; Lu F; Tang J
Drug Deliv; 2022 Dec; 29(1):702-713. PubMed ID: 35236203
[TBL] [Abstract][Full Text] [Related]
7. Exosomes derived from γδ-T cells synergize with radiotherapy and preserve antitumor activities against nasopharyngeal carcinoma in immunosuppressive microenvironment.
Wang X; Zhang Y; Mu X; Tu CR; Chung Y; Tsao SW; Chan GC; Leung WH; Lau YL; Liu Y; Tu W
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35105688
[TBL] [Abstract][Full Text] [Related]
8. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
[TBL] [Abstract][Full Text] [Related]
9. Efficient Delivery of Tyrosinase Related Protein-2 (TRP2) Peptides to Lymph Nodes using Serum-Derived Exosomes.
Park O; Choi ES; Yu G; Kim JY; Kang YY; Jung H; Mok H
Macromol Biosci; 2018 Dec; 18(12):e1800301. PubMed ID: 30407735
[TBL] [Abstract][Full Text] [Related]
10. Development of resiquimod-loaded modified PLA-based nanoparticles for cancer immunotherapy: A kinetic study.
Thauvin C; Widmer J; Mottas I; Hocevar S; Allémann E; Bourquin C; Delie F
Eur J Pharm Biopharm; 2019 Jun; 139():253-261. PubMed ID: 30981947
[TBL] [Abstract][Full Text] [Related]
11. Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy.
Figueiredo P; Lepland A; Scodeller P; Fontana F; Torrieri G; Tiboni M; Shahbazi MA; Casettari L; Kostiainen MA; Hirvonen J; Teesalu T; Santos HA
Acta Biomater; 2021 Oct; 133():231-243. PubMed ID: 33011297
[TBL] [Abstract][Full Text] [Related]
12. Formulation and preclinical evaluation of a toll-like receptor 7/8 agonist as an anti-tumoral immunomodulator.
Lu R; Groer C; Kleindl PA; Moulder KR; Huang A; Hunt JR; Cai S; Aires DJ; Berkland C; Forrest ML
J Control Release; 2019 Jul; 306():165-176. PubMed ID: 31173789
[TBL] [Abstract][Full Text] [Related]
13. Ivermectin Enhanced Antitumor Activity of Resiquimod in a Co-Loaded Squalene Emulsion.
Zhang Z; Kuo JC; Zhang C; Huang Y; Lee RJ
J Pharm Sci; 2022 Nov; 111(11):3038-3046. PubMed ID: 35697319
[TBL] [Abstract][Full Text] [Related]
14. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
[TBL] [Abstract][Full Text] [Related]
15. Thermosensitive Gel-Based Formulation for Intratumoral Delivery of Toll-Like Receptor 7/8 Dual Agonist, MEDI9197.
Fakhari A; Nugent S; Elvecrog J; Vasilakos J; Corcoran M; Tilahun A; Siebenaler K; Sun J; Subramony JA; Schwarz A
J Pharm Sci; 2017 Aug; 106(8):2037-2045. PubMed ID: 28456734
[TBL] [Abstract][Full Text] [Related]
16. Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy.
Rodell CB; Ahmed MS; Garris CS; Pittet MJ; Weissleder R
Theranostics; 2019; 9(26):8426-8436. PubMed ID: 31879528
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.
Ilyinskii PO; Roy CJ; O'Neil CP; Browning EA; Pittet LA; Altreuter DH; Alexis F; Tonti E; Shi J; Basto PA; Iannacone M; Radovic-Moreno AF; Langer RS; Farokhzad OC; von Andrian UH; Johnston LP; Kishimoto TK
Vaccine; 2014 May; 32(24):2882-95. PubMed ID: 24593999
[TBL] [Abstract][Full Text] [Related]
18. The TLR7/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer.
Zhou J; Xu Y; Wang G; Mei T; Yang H; Liu Y
Int J Oncol; 2022 Jul; 61(1):. PubMed ID: 35552764
[TBL] [Abstract][Full Text] [Related]
19. Carboxymethylated Alginate-Resiquimod Micelles Reverse the Immunosuppressive Tumor Microenvironment and Synergistically Enhance the Chemotherapy and Immunotherapy for Gastric Cancer.
Chen J; Liu X; Zhao S; Chen H; Lu T; Wang J; Han J; Wu W; Shen X; Li C
ACS Appl Mater Interfaces; 2023 Aug; 15(30):35999-36012. PubMed ID: 37477904
[TBL] [Abstract][Full Text] [Related]
20. Nanomaterials-Mediated Co-Stimulation of Toll-Like Receptors and CD40 for Antitumor Immunity.
Yan J; Zhang Y; Du S; Hou X; Li W; Zeng C; Zhang C; Cheng J; Deng B; McComb DW; Zhao W; Xue Y; Kang DD; Cheng X; Dong Y
Adv Mater; 2022 Nov; 34(47):e2207486. PubMed ID: 36121735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
